Pharmacologic treatment of binge eating disorder

Int J Eat Disord. 2003:34 Suppl:S74-88. doi: 10.1002/eat.10207.

Abstract

Objective: To review the findings from pharmacologic trials of binge eating disorder (BED) and to provide guidelines for pharmacologic treatment.

Methods: The literature was searched for studies of pharmacologic treatment of BED and related conditions, such as nonpurging bulimia nervosa.

Results: Placebo-controlled studies of desipramine, fluvoxamine, fluoxetine, sertraline, citalopram, dexfenfluramine, sibutramine, and topiramate have demonstrated the efficacy of these agents in the treatment of BED. An open trial of venlafaxine has offered preliminary evidence for the efficacy of this medication. Guidelines for pharmacologic management of BED are provided.

Conclusions: The literature offers support for the use of agents from three categories of medication (antidepressants, appetite suppressants, and anticonvulsants) in the treatment of BED.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Anticonvulsants / therapeutic use*
  • Antidepressive Agents / therapeutic use*
  • Appetite Depressants / therapeutic use*
  • Bulimia / diagnosis
  • Bulimia / drug therapy*
  • Bulimia / psychology
  • Humans
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Treatment Outcome

Substances

  • Anticonvulsants
  • Antidepressive Agents
  • Appetite Depressants
  • Serotonin Uptake Inhibitors